Shionogi Plans Greater Presence In U.S., U.K. Markets
This article was originally published in PharmAsia News
Japan's Shionogi plans to concentrate on the foreign market with an aim to triple the foreign share of its overall sales. Foreign business currently accounts for only 10 percent of Shionogi sales and its goal is to boost that amount to 30 percent. The firm plans to create a wholly owned subsidiary for development in the United Kingdom and apply for approval of three products in the United States in 2011. To market those drugs two years later, Shionogi is considering acquisition of a midsize U.S. drug maker. The drugs include its first product developed abroad, an obesity treatment, now in Phase III trials. (Click here for more - a subscription may be required
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.